期刊文献+

含氯法齐明方案治疗耐多药肺结核近期疗效观察 被引量:7

Contain clofazimine solution treatment of multi-drug resistant tuberculosis in the near future curative effect observation
下载PDF
导出
摘要 目的:观察和评价含氯法齐明方案治疗耐多药肺结核近期(治疗前6月)效果。方法:选取在我院的耐多药肺结核患者60例,随机分为对照组和治疗组,对照组30例采用6Z、Am、Lfx、X、Y/12Lfx、Z、X、Y治疗方案;治疗组30例采用6Z、Am、Lfx、Cfz、X、Y/12Z、Lfx、Cfz X、Y治疗方案。其中X、Y为根据药敏试验敏感的药物或既往未用过的抗结核药物。结果:治疗组和对照组在治疗第6个月末痰菌阴转率分别为56.7%、30.0%,两组比较具有极显著性差异(P<0.01);治疗组和对照组在治疗第6个月末肺部影像学改变有效例数分别为24例、15例,有效率分别为80%、50%,两组肺部影像学改变有效率相比有极显著性差异(P<0.01)。结论:含氯法齐明方案治疗耐多药肺结核近期疗效显著。 Objective:Observation and evaluation including clofazimine solution treatment of multi‐drug resistant tuberculosis (before 6 month) recent effect .Methods:Selection 60 patients with multidrug‐resistant tuber‐culosis in our hospital ,were randomly divided into control group and treatment group and control group 30 cases , treatment group 30 cases .Treatment control group 6 Am ,Lfx ,X ,Y ,Z ,/12 Lfx ,Z ,X ,Y ;Treatment group:6 Z ,Am ,Lfx ,Cfz ,X ,Y /12 ,Lfx ,Cfz X ,Y ,Z .(X ,Y for sensitive drugs or according to antimicrobial suscepti‐bility test always unused anti‐tb drugs) .Results :Treatment group and control group in the treatment of the first 6 end phlegm germ feminine changed rate was respectively :56 .7% ,30 .0% (P 〈 0 .01) statistically significant ;Treatment group and control group in the treatment of the first of June lung imaging change:effective cases of 25 ca‐ses ,13 cases respectively ,effectiveness 80% ,50% respectively(P 〈 0 .01) ,with statistical significance .Conclu‐sion :Contain clofazimine solution treatment of multi‐drug resistant tuberculosis in the near future curative effect is distinct .
作者 石海萍 韩莉
出处 《陕西医学杂志》 CAS 2015年第5期605-607,共3页 Shaanxi Medical Journal
基金 陕西省卫生厅科研项目基金(2012D65)
关键词 结核 肺/药物疗法 药物疗法 联合 @含氯法齐明方案 Tuberculosis, pulmonary/drug therapy Drug therapy,combination @Contain elofazimine solution
  • 相关文献

参考文献7

二级参考文献93

  • 1陆宇,王彬,郑梅琴,赵伟杰,李芃.应用Alamar Blue和MTT测定抗结核药物最低抑菌浓度的研究[J].中国防痨杂志,2007,29(6):499-501. 被引量:37
  • 2丁嘉安,谢冬.肺结核外科治疗新进展[J].结核病与肺部健康杂志,2012,1(1). 被引量:16
  • 3Reddy VM, O' Sullivan JF, Gangadharam PR. Antimycobacterial activities of riminophenazines. J Antimicrob Chemother,1999,43 : 615-623.
  • 4Jagannath C, Reddy MV, Kailasam S, et al. Chemotherapeutic activity of clofazimine and its analogues against Mycobacterium tuberculosis in vitro, intracellular, and in vivo studies. Am J Respir Crit Care Med, 1995,151 : 1083-1086.
  • 5Ji B, Lounis N, Truffot-Pernot C, et al. Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. Antimicrob Agents Chemother, 1994,38: 2521-2529.
  • 6Adams LB, Sinha I, Franzblau SG, et al. Effective treatment of acute and chronic murine tuberculosis with liposome-encapsulated clofazimine. Antimicrob Agents Chemother, 1999,43 : 1638-1643.
  • 7Reddy VM, Nadadhur G, Daneluzzi D, et al. Antituberculosis activities of clofazimine and its new analogs B4154 and 134157. Antimicrob Agents Chemother, 1996,40:633-636.
  • 8Nix DE, Adam RD, Auclair B, et al. Phannacokinetics and relative bioavailability of clofazimine in relation to food, orange juice and antacid. Tuberculosis (Edinb) , 2004,84:365-373.
  • 9Jadhav MV, Sathe AG, Deore SS, et al. Tissue concentration, systemic distribution and toxicity of clofazimine-an autopsy study. Indian J Pathol Micmbiol,2004,47: 281-283.
  • 10O' Connor R, O' Sullivan JF, O' Kennedy R. The pharmacology, metabolism, and chemistry of clofazimine. Drug Metab Rev, 1995, 27:591-614.

共引文献250

同被引文献56

引证文献7

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部